Ehrlich and Metchnikoff's Nobel Prize, 1908

Germ theory had identified causes of many infections, but identifying a microbe did not explain why exposure produced different outcomes or why vaccination protected. The new problem was the host's response. A historical review by Stefan Kaufmann places Metchnikoff and Ehrlich within this larger network of vaccination, bacteriology, comparative biology, serum therapy, and laboratory medicine.

1. 1882–1884: while studying marine invertebrates at Messina in Sicily, Metchnikoff connected intracellular digestion with defence. His later account of inserting a splinter into a transparent starfish larva describes the inspiration for the theory; it is a retrospective recollection, not neutral evidence that nobody had previously observed cells ingesting particles. Papers from 1883–1884 extended the claim toward inflammation and immunity.
2. 1888: the Institut Pasteur opened in Paris, and Metchnikoff led a laboratory there. The setting gave him colleagues, pupils, animals, cultures, microscopes, and international audiences with which to test and defend the phagocyte theory.
3. 1890–1894: Emil von Behring and Shibasaburo Kitasato showed that serum from immunized animals could transfer protection against diphtheria or tetanus toxins. Clinical use of diphtheria antitoxin and experiments showing destruction of some bacteria in body fluids strengthened humoral accounts—humoral here means action in fluids, especially serum.
4. 1896–1900: Ehrlich directed a Prussian serum-testing institute, first at Steglitz and from 1899 at Frankfurt am Main. Practical variation in diphtheria toxin and antitoxin preparations helped drive his quantitative work. In 1897 he elaborated the side-chain theory; in 1900 he and Julius Morgenroth introduced “receptor” while studying haemolysis, and Ehrlich presented his immunological programme in the Royal Society's Croonian Lecture.
5. 1903: Almroth Wright and Stewart Douglas described serum substances they called opsonins, from a word meaning to prepare food. Because these substances made microbes easier for phagocytes to ingest, opsonization offered an experimental bridge between soluble and cellular action.
6. 10–11 December 1908: the Nobel award was presented in Stockholm; both laureates lectured the following day. Their lectures surveyed achievements but also continued to defend distinct interpretations. The ceremony conferred authority on the field, not closure on its controversies.

Metchnikoff did not begin as a clinician studying human patients. His route ran through embryology, evolution, and intracellular digestion in organisms including starfish larvae and water fleas. Alfred Tauber and Leon Chernyak's critical intellectual history shows why this background matters: Metchnikoff's theory concerned the active maintenance of an organism, not simply a modern checklist of immune-cell functions.

At the Institut Pasteur he and collaborators extended observations from simple, transparent animals to experimental infections in vertebrates. His categories of macrophages and microphages were historical classifications based on size, form, and behaviour; they should not be assumed to correspond exactly to present-day cell categories. Nor did he deny every role to fluids. His 1905 Immunity in Infective Diseases discussed fixatives, antitoxins, and acquired immunity while trying to incorporate them into a phagocyte-centred account.

The 1905 book and Metchnikoff's 1908 Nobel lecture are valuable primary sources because they show his mature argument, vocabulary, and choice of evidence. They are also advocacy: both were written after years of controversy to persuade readers that phagocytosis held the central place in immunity. Metchnikoff himself acknowledged in the lecture that much work had been carried out by pupils at the Institut Pasteur.

Ehrlich's earlier staining research encouraged him to interpret selective uptake as a chemical affinity between substances and cells. Diphtheria antitoxin then created a practical problem: preparations changed in strength and could not be dosed reliably without a comparative standard. His testing work connected state regulation, manufacturers, animal experiments, and the treatment of patients—many of them children with diphtheria.

In the side-chain model, a toxin bound selectively to a structure attached to a cell; the cell responded by overproducing such side chains and releasing them into the blood as antitoxins. A study based on Ehrlich's publications, correspondence, and laboratory records cautions against reading this as a pre-planned march to the modern receptor: Cay-Rüdiger Prüll traces how experimental problems, career constraints, Prussian support, and disputes reshaped the idea between 1878 and 1905.

The theory was also collective. Julius Morgenroth coordinated much of the experimental work and co-authored the haemolysin papers in which “receptor” entered Ehrlich's immunological vocabulary. Assistants performed extensive animal experiments, while clinicians and serum producers supplied material problems and tests. Credit centred on Ehrlich because he directed the programme and the Nobel institution rewarded named individuals, not because he worked alone.

Serum therapy was not an abstract demonstration. Producers immunized horses, drew their blood, separated the serum, and tested potency largely in guinea pigs. The Wellcome Physiological Research Laboratories archive preserves stables, production, testing, and animal-experiment records from one British manufacturer. Such records reveal forms of labour and animal use that prize biographies usually place outside the frame.

Potency standards improved comparability but did not remove every danger. Horse serum could produce adverse reactions, and contaminated biological products could transmit infection. In St Louis in 1901, antitoxin from a horse infected with tetanus killed thirteen children; the episode contributed to the United States Biologics Control Act of 1902. The case, documented in a Wellcome Collection history, shows why immunology's laboratory measurements were inseparable from manufacturing, inspection, clinical judgment, and public trust.

The 1908 prize itself did not introduce a treatment and should not be described as a cure. It recognized explanations and experimental methods that had grown alongside vaccination and serum therapy. Their clinical consequences depended on institutions able to produce, regulate, distribute, and administer biological products safely.

It is tempting to translate Metchnikoff directly into “innate immunity” and Ehrlich directly into “adaptive immunity.” That shorthand is useful only with caution. Metchnikoff wrote about natural and acquired immunity; Ehrlich's soluble antitoxins originated in a theory of cell receptors; and today's “cell-mediated immunity” often refers to lymphocyte functions unknown in 1908. The historical cellular–humoral debate therefore does not map cleanly onto current categories.

Opsonins were one reason a simple opposition weakened: a fluid factor could alter a microbe so that a cell engulfed it more readily. Jules Bordet's work on serum factors, later associated with complement, likewise challenged Ehrlich's particular mechanism without making cells irrelevant. These were not minor adjustments to two finished systems; researchers were still deciding which experimental effects were stable and how new terms related to one another.

The historian Alfred Tauber's analysis of confidential Nobel evaluations argues that the committee's acceptance of Metchnikoff was qualified and that the joint award rested on an apparent complementarity between selected parts of the programmes. The prize is therefore best read as an institutional settlement at one moment, not proof that a complete synthesis existed in 1908. Later histories turned that settlement into a tidy origin story; the evidence shows a more collective and unresolved field.